The Technical Analyst
Axonics Modulation [AXNX]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Axonics Modulation Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.21% $67.20
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 427.43 mill |
| EPS: | -0.120 |
| P/E: | -560.00 |
| Earnings Date: | Apr 29, 2024 |
| SharesOutstanding: | 51.00 mill |
| Avg Daily Volume: | 0.993 mill |
| RATING 2024-04-17 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -560.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.52x |
| Company: PE -560.00 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 66.69 - 67.73 ( +/- 0.77%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-31 | Sama Rinda | Buy | 28 000 | Common Stock |
| 2024-01-31 | Sama Rinda | Sell | 17 500 | Performance-Based Restricted Stock Units |
| 2024-01-31 | Noblett Karen | Buy | 27 500 | Common Stock |
| 2024-01-31 | Noblett Karen | Sell | 11 288 | Common Stock |
| 2024-01-31 | Noblett Karen | Sell | 15 000 | Performance-Based Restricted Stock Units |
| INSIDER POWER |
|---|
| -1.52 |
| Last 98 transactions |
| Buy: 597 788 | Sell: 539 127 |
Forecast:
16:00 - $67.28
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $67.28
Forecast 2: 16:00 - $67.28
Forecast 3: 16:00 - $67.28
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $67.20 (-0.21% ) |
| Volume | 0.582 mill |
| Avg. Vol. | 0.993 mill |
| % of Avg. Vol | 58.59 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AXNX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $67.72 | N/A | Active |
|---|
AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-22 16:01:00 - Press Release
Axonics Stockholders Approve Merger Agreement With Boston Scientific
Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) announced that its stockholders have voted today to adopt axonics' merger agreement with boston scientific corporation (nyse: bsx). according to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of axonics' common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. final voting results, as tabulated by an independ.
2024-03-21 16:54:00 - Press Release
Axonics Provides Update On Inter Partes Review Proceedings
Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) today announced that the patent trial and appeal board (ptab) of the u.s. patent and trademark office has issued written decisions on two medtronic patents that axonics is contesting. the ptab issued its decision with respect to patent nos. 8,626,314 (“the ‘314 patent”) and 8,036,756 (“the ‘756 patent”). medtronic has asserted these patents, which expired in 2021 and 2022, against axonics' proprietary tined lead design. today, the pt.
2024-03-14 06:00:00 - Press Release
Axonics Receives Ce Mark Approval For Fourth-generation Rechargeable Sacral Neuromodulation System
Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the axonics r20™ rechargeable sacral neuromodulation (snm) system has received ce mark approval. the r20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once.
2024-02-29 16:01:00 - Press Release
Axonics Responds To Itc Action By Medtronic
Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) today announced that it has received notice that medtronic has filed a complaint with the u.s. international trade commission (itc), along with a parallel action in u.s. district court for the district of delaware. the complaint alleges that axonics infringes two medtronic patents that purportedly relate to a “patient programmer with automated mri compatibility verification” for an implantable medical device. “we believe medtronic's.
2024-02-27 15:30:00 - Press Release
Axonics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Axonics, Inc. - Axnx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of axonics, inc. (nasdaqgs: axnx) to boston scientific corporation (nyse: bsx). under the terms of the proposed transaction, shareholders of axonics will receive $71.00 in cash for each share of axonics that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequa.
Latest News
2024-03-29 13:01:09 - Zacks Investment Research
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-15 09:56:10 - Zacks Investment Research
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
2024-02-28 18:41:05 - Zacks Investment Research
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago.
2024-01-31 09:05:28 - Zacks Investment Research
4 Stocks Backed by High Efficiency to Enrich Your Portfolio
Invest in companies like Axonics (AXNX), Enerpac Tool Group (EPAC), Cardinal Health (CAH) and Acuity Brands (AYI) due to higher efficiency levels.
2024-01-08 19:38:18 - The Motley Fool
Why Axonics Stock Soared Today
Axonics has agreed to be acquired by Boston Scientific for $71 per share in cash. Assuming the deal receives the approval of shareholders and regulators, it should close in the first half of 2024.
2024-01-08 11:28:51 - InvestorPlace
Why Is Axonics (AXNX) Stock Up 20% Today?
Axonics (NASDAQ: AXNX ) stock is rising higher on Monday following news that Boston Scientific (NYSE: BSX ) is acquiring the company for $3.7 billion. That has Boston Scientific agreeing to purchase Axonics for $71 in cash per share.
2024-01-08 11:13:47 - Schaeffers Research
Axonix Stock Hits 52-Week High on Buyout Buzz
The shares of Axonix Inc (NASDAQ:AXNX) are soaring today, after news that Boston Scientific (BSX) is acquiring the medical equipment name for approximately $3.7 billion, or $71 per share.
2024-01-08 08:18:00 - Barrons
Axonics Stock Soars. It's Being Acquired By Boston Scientific In $3.7 Billion Deal.
2024-01-08 07:09:36 - Reuters
Boston Scientific to buy Axonics for $3.7 billion
Boston Scientific said on Monday it had agreed to buy medtech company Axonics Inc for $3.7 billion.
2023-12-27 16:01:00 - Business Wire
Axonics to Present at the J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024. Interested parties may access a live webcast and replay of the presentation by visiting the Axonics investor relations website. About Axonics Axonics is a global medical techn.